• news.cision.com/
  • Attana/
  • New publication - Attana’s technology was used to develop a specific antibody fragment for treatment of inflammatory diseases

New publication - Attana’s technology was used to develop a specific antibody fragment for treatment of inflammatory diseases

Report this content

A new paper has been published in mAbs by Dr. Richter and co-workers at University of Stuttgart. The aim of the study was to develop a novel, monovalent antibody inhibitor of inflammatory activation with extended serum half-life. Attana's QCM technology was used to optimize the specific interaction properties of the inhibitor.

Tumor necrosis factor (TNF) plays a central role in the immune system, especially during inflammation and infection. Dysregulated expression of TNF is associated with severe inflammatory conditions and has been reported to be involved in the development of diseases such as type II diabetes, Crohns disease and rheumatoid arthritis (RA). Five TNF-targeting therapeutics (infliximab, adalimumab, certolizumab pegol, golimumab, etanercept) are presently approved and used for the treatment of different inflammatory diseases, resulting in dramatic improvement of the patientsquality of life. However, the undisputable clinical success of anti-TNF therapeutics has limitations. Depending on the applied therapeutics, 1333% of treated patients do not respond to treatment and up 46% stop to respond to therapy. Moreover, anti-TNF therapy can be associated with severe side-effects, including infections, tuberculosis reactivation, development of malignancies (e.g., lymphomas) and neurological conditions (demyelinating disease), and the exacerbation of existing inflammatory symptoms.

In this study, Richter et al. applied a newly developed novel monovalent antibody. The concept  has the benefits of improved specificity in combination with prolonged serum half-life, which suggest improved therapeutic properties. Attana´s QCM technology has been used to optimize the interaction and serum half-life propertiess.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com





Documents & Links